{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervix+Neoplasms&page=12",
    "query": {
      "condition": "Cervix Neoplasms",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 918,
    "total_pages": 92,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervix+Neoplasms&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervix+Neoplasms&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T12:43:28.079Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05021237",
      "title": "Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy for Metastatic Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage IV Cervical Cancer FIGO 2018",
        "Adenosquamous Carcinoma of Cervix",
        "Cervical Cancer",
        "Metastasis"
      ],
      "interventions": [
        {
          "name": "Ultra-fractionated radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2022-02-01",
      "completion_date": "2026-06-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05021237"
    },
    {
      "nct_id": "NCT07406087",
      "title": "Navigation Intervention for Adolescent and Young Adult Cancer Survivors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Testicular Cancer",
        "Colon Rectal Cancer",
        "Melanoma (Skin Cancer)",
        "Endometrial Cancer",
        "Sarcoma",
        "Thyroid Cancer"
      ],
      "interventions": [
        {
          "name": "Adapted patient navigation program targeting adolescent and young adult cancer survivors",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 25,
      "start_date": "2026-03-15",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07406087"
    },
    {
      "nct_id": "NCT01536392",
      "title": "Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer of the Cervix"
      ],
      "interventions": [
        {
          "name": "Granisetron",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Study Drug Diary",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 76,
      "start_date": "2012-03",
      "completion_date": "2019-10-03",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01536392"
    },
    {
      "nct_id": "NCT00025233",
      "title": "Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Squamous Cell Carcinoma",
        "Recurrent Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2002-04",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2019-07-24",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00025233"
    },
    {
      "nct_id": "NCT03674567",
      "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "FLX475 (tivumecirnon)",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RAPT Therapeutics, Inc., a member of the GSK plc group of companies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2018-09-25",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 19,
      "location_summary": "Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03674567"
    },
    {
      "nct_id": "NCT00084123",
      "title": "Healing Touch and Relaxation Therapies in Cervical Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervix Neoplasms"
      ],
      "interventions": [
        {
          "name": "Healing Touch Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Relaxation Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2002-09",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2009-07-10",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084123"
    },
    {
      "nct_id": "NCT00004936",
      "title": "MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "iodinated contrast dye",
          "type": "DRUG"
        },
        {
          "name": "computed tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "gadopentetate dimeglumine",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "American College of Radiology Imaging Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-04",
      "completion_date": "2002-10",
      "has_results": false,
      "last_update_posted_date": "2013-01-28",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 2,
      "location_summary": "Morristown, New Jersey • New York, New York",
      "locations": [
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004936"
    },
    {
      "nct_id": "NCT03752398",
      "title": "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Excluding Uveal Melanoma)",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Cancer",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced Solid Tumors",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "XmAb®23104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Yervoy® (ipilimumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2019-05-01",
      "completion_date": "2024-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 18,
      "location_summary": "San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03752398"
    },
    {
      "nct_id": "NCT02270021",
      "title": "Decreasing Over Screening and Treatment of Cervical Precancers in Young Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Provider Mobile Application (ProvAPP)",
          "type": "OTHER"
        },
        {
          "name": "ProvAPP + Patient Educational Tool (Tab)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "29 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 29 Years · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2014-07-24",
      "completion_date": "2019-08-30",
      "has_results": false,
      "last_update_posted_date": "2019-09-25",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • San Francisco, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270021"
    },
    {
      "nct_id": "NCT06238635",
      "title": "Dostarlimab and Cobolimab in Advanced Cervical Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Advanced Cervical Carcinoma",
        "Metastatic Cervical Cancer",
        "Metastatic Cervical Carcinoma",
        "Recurrent Cervical Carcinoma"
      ],
      "interventions": [
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Cobolimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Meghan Shea",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 66,
      "start_date": "2024-03-11",
      "completion_date": "2027-07-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-28T12:43:28.079Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06238635"
    }
  ]
}